Suppr超能文献

白塞病中的眼部炎症:眼部并发症及视力丧失的发生率

Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity.

作者信息

Kaçmaz R Oktay, Kempen John H, Newcomb Craig, Gangaputra Sapna, Daniel Ebenezer, Levy-Clarke Grace A, Nussenblatt Robert B, Rosenbaum James T, Suhler Eric B, Thorne Jennifer E, Jabs Douglas A, Foster C Stephen

机构信息

Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts 21042, USA.

出版信息

Am J Ophthalmol. 2008 Dec;146(6):828-36. doi: 10.1016/j.ajo.2008.06.019. Epub 2008 Aug 16.

Abstract

PURPOSE

To estimate the risk of structural ocular complications and loss of visual acuity (VA) in cases of Behçet disease (BD) and to evaluate potential risk and protective factors for these events.

DESIGN

Retrospective cohort study.

METHODS

A total of 168 consecutive patients with BD-associated ocular inflammation treated at five academic center ocular inflammation subspecialty practices were included. Clinical data for these patients were ascertained by standardized chart review. Main outcome measures included VA, structural ocular complications of inflammation, and intraocular pressure (IOP).

RESULTS

Over a median follow-up of 1.05 years, the incidence of specific structural complications and IOP disturbances were common: the incidence rate of any ocular complication was 0.45 per eye-year (EY). Rates of loss of VA to 20/50 or worse and to 20/200 or worse were 0.12 per EY and 0.09 per EY, respectively. Risk factors for loss of VA during follow-up were persistent inflammatory activity, presence of posterior synechiae, presence of hypotony, and presence of elevated IOP. In a time-dependent analysis, current activity of ocular inflammation was associated with an increased risk of loss of VA to 20/50 or worse (relative risk [RR], 2.45; 95% confidence interval [CI], 1.1 to 5.5; P = .03) and to 20/200 or worse (RR, 2.67; 95% CI, 1.2 to 5.8; P = .01).

CONCLUSIONS

Loss of VA and occurrence of ocular complications were common in patients with ocular inflammation associated with BD, even with aggressive therapy. Ongoing inflammation during follow-up, presence or occurrence of posterior synechiae, hypotony, and elevated IOP were associated with an increased risk of loss of VA.

摘要

目的

评估白塞病(BD)患者发生眼部结构并发症和视力(VA)丧失的风险,并评估这些事件的潜在风险和保护因素。

设计

回顾性队列研究。

方法

纳入了在五个学术中心眼科炎症专科接受治疗的168例连续的BD相关性眼部炎症患者。通过标准化图表审查确定这些患者的临床数据。主要结局指标包括VA、炎症性眼部结构并发症和眼压(IOP)。

结果

在中位随访1.05年期间,特定结构并发症和IOP紊乱的发生率很常见:任何眼部并发症的发生率为每眼年(EY)0.45。VA降至20/50或更差以及降至20/200或更差的发生率分别为每EY 0.12和每EY 0.09。随访期间VA丧失的危险因素包括持续性炎症活动、存在后粘连、存在低眼压和IOP升高。在时间依赖性分析中,眼部炎症的当前活动与VA降至20/50或更差(相对风险[RR],2.45;95%置信区间[CI],1.1至5.5;P = .03)以及降至20/200或更差(RR,2.67;95%CI,1.2至5.8;P = .01)的风险增加相关。

结论

即使进行积极治疗,BD相关性眼部炎症患者中VA丧失和眼部并发症的发生也很常见。随访期间的持续炎症、后粘连的存在或发生、低眼压和IOP升高与VA丧失风险增加相关。

相似文献

1
Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity.
Am J Ophthalmol. 2008 Dec;146(6):828-36. doi: 10.1016/j.ajo.2008.06.019. Epub 2008 Aug 16.
3
Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss.
Am J Ophthalmol. 2007 May;143(5):840-846. doi: 10.1016/j.ajo.2007.01.033. Epub 2007 Mar 23.
4
Hypopyon in patients with uveitis.
Ophthalmology. 2010 Feb;117(2):366-72. doi: 10.1016/j.ophtha.2009.07.025. Epub 2009 Dec 14.
5
Incidence rates and risk factors for ocular complications and vision loss in HLA-B27-associated uveitis.
Am J Ophthalmol. 2010 Oct;150(4):534-542.e2. doi: 10.1016/j.ajo.2010.04.031.
6
Risk of Hypotony in Juvenile Idiopathic Arthritis-Associated Uveitis.
Am J Ophthalmol. 2016 Sep;169:113-124. doi: 10.1016/j.ajo.2016.06.026. Epub 2016 Jun 23.
8
Clinical Features and Incidence Rates of Ocular Complications in Patients With Retinal Vasculitis.
Am J Ophthalmol. 2017 Jul;179:171-178. doi: 10.1016/j.ajo.2017.05.007. Epub 2017 May 10.
9
Juvenile idiopathic arthritis-associated uveitis at an Italian tertiary referral center: clinical features and complications.
Ocul Immunol Inflamm. 2015 Feb;23(1):74-81. doi: 10.3109/09273948.2013.855798. Epub 2013 Dec 11.
10
Ocular morbidities of juvenile idiopathic arthritis-associated uveitis in adulthood: results from a tertiary center study.
Graefes Arch Clin Exp Ophthalmol. 2016 Sep;254(9):1841-9. doi: 10.1007/s00417-016-3340-z. Epub 2016 Apr 15.

引用本文的文献

1
Inflammatory hematological ratios and subclinical microvascular changes of fundus in Behçet disease.
Graefes Arch Clin Exp Ophthalmol. 2025 Aug 13. doi: 10.1007/s00417-025-06896-5.
3
Use of corticosteroids in non-infectious uveitis - expert consensus in Taiwan.
Ann Med. 2024 Dec;56(1):2352019. doi: 10.1080/07853890.2024.2352019. Epub 2024 May 15.
4
Behçet's Disease, Pathogenesis, Clinical Features, and Treatment Approaches: A Comprehensive Review.
Medicina (Kaunas). 2024 Mar 29;60(4):562. doi: 10.3390/medicina60040562.
5
Efficacy of golimumab in patients with refractory non-infectious panuveitis.
Sci Rep. 2024 Jan 25;14(1):2179. doi: 10.1038/s41598-024-52526-1.
6
The challenge of ocular inflammation in systemic vasculitis: How to address inequalities of care?
Rheumatol Immunol Res. 2023 Apr 18;4(1):1-3. doi: 10.2478/rir-2023-0001. eCollection 2023 Mar.
7
Ocular Behçet Disease-Clinical Manifestations, Treatments and Outcomes According to Age at Disease Onset.
Biomedicines. 2023 Feb 19;11(2):624. doi: 10.3390/biomedicines11020624.
8
Ten-year follow-up of infliximab treatment for uveitis in Behçet disease patients: A multicenter retrospective study.
Front Med (Lausanne). 2023 Jan 20;10:1095423. doi: 10.3389/fmed.2023.1095423. eCollection 2023.
9
Research Progress of Artificial Intelligence Image Analysis in Systemic Disease-Related Ophthalmopathy.
Dis Markers. 2022 Jun 24;2022:3406890. doi: 10.1155/2022/3406890. eCollection 2022.

本文引用的文献

2
Ocular features of Behcet's disease: an international collaborative study.
Br J Ophthalmol. 2007 Dec;91(12):1579-82. doi: 10.1136/bjo.2007.123554.
3
Behçet's disease: global epidemiology of an Old Silk Road disease.
Br J Ophthalmol. 2007 Dec;91(12):1573-4. doi: 10.1136/bjo.2007.124875.
5
Long-term infliximab treatment for Behçet's disease.
Jpn J Ophthalmol. 2007 May-Jun;51(3):239-40. doi: 10.1007/s10384-006-0424-z. Epub 2007 Jun 7.
6
Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Jpn J Ophthalmol. 2007 May-Jun;51(3):191-6. doi: 10.1007/s10384-006-0425-y. Epub 2007 Jun 7.
8
Prevalence and clinical aspects of Behcet's disease in the north of Israel.
Clin Rheumatol. 2007 Apr;26(4):555-60. doi: 10.1007/s10067-006-0349-4. Epub 2006 Aug 1.
10
Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement.
Graefes Arch Clin Exp Ophthalmol. 2005 Nov;243(11):1147-52. doi: 10.1007/s00417-005-0005-8. Epub 2005 Jun 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验